Le Lézard
Classified in: Health, Business
Subject: OFR

PureHealth IPO Receives Staggering Demand, Gross Orders Received of AED 265 Billion


ABU DHABI, UAE, Dec. 12, 2023 /PRNewswire/ -- PureHealth Holding PJSC (Public Joint Stock Company under incorporation; the "Company"), today announces the successful completion of the subscription process for its initial public Offering ("IPO" or the "Offering") on the First Market of the Abu Dhabi Securities Exchange ("ADX"). The Company confirmed the fixed price for the Offering which has been set at AED 3.26 per ordinary share (the "Final Offer Price") with an Offering size of 1.11 billion ordinary shares ("Offer Shares"), equivalent to 10 percent of its total issued share capital. The Offering witnessed significant demand from investors within the UAE and the region, resulting in multiple oversubscriptions. The total gross demand for the Offering surpassed over AED 265 billion.

The Professional Subscribers tranche attracted demand of AED 186 billion reflecting an oversubscription level of 54 times. Meanwhile, the Retail offering witnessed tremendous appetite from investors, accumulating demand in excess of AED 78 billion, marking an oversubscription level of 483 times.

Commenting on the announcement, Farhan Malik, Founder and Managing Director of PureHealth, said: "There has been overwhelming demand for our IPO. This is a resounding endorsement of the market's confidence in our achievements, the management's execution capability, and our vision for growth. The IPO unlocks PureHealth's credentials in transforming healthcare systems, underscoring our commitment to shaping the future of healthcare through continuous innovation and an unwavering pursuit of excellence, where we take Pure Health from Abu Dhabi to the World.''

The Offering will generate gross proceeds of AED 3.62 billion for the Company. On listing, the Company's market capitalization is expected to reach AED 36.2 billion.

The Constitutive General Assembly Meeting for conversion to PJSC is on 15 December 2023. Listing and trading commencement of PureHealth's shares on ADX are expected to take place on 20 December 2023, subject to market conditions and regulatory approvals in the UAE. The shares will trade under the symbol "PureHealth" and ISIN "AEE01362P238."  At listing, provided that the offering shares are fully subscribed, the Founders will retain a 90% stake in the Company. First Abu Dhabi Bank PJSC acted as Lead Manager and Lead Receiving Bank. International Securities LLC was appointed as the Lead Placement Agent.

About PureHealth

By advancing the science of longevity, PureHealth is introducing the healthcare of the future from the UAE to the rest of the world. PureHealth is the largest integrated healthcare platform in the Middle East, with an ecosystem that challenges lifespans and reimagines health spans. With 25+ hospitals, 100+ clinics, multiple diagnostic centers, health insurance solutions, pharmacies, health tech, procurement, investments and more, its groundbreaking innovations are at the forefront of healthcare, as the company is on a mission to unlock time for humankind.

PureHealth's network of healthcare facilities across Abu Dhabi and the Northern Emirates comprises: 

To learn more, please visit www.purehealth.ae

Photo - https://mma.prnewswire.com/media/2298732/PureHealth.jpg

SOURCE PureHealth


These press releases may also interest you

at 03:01
'Textbook of Tinnitus' is a comprehensive textbook that describes tinnitus, how it is caused, and state-of-the art interventions such as Lenire.Top-ranked tinnitus expert authors of the Textbook of Tinnitus state that Lenire's clinical trial results...

at 03:00
In a significant stride towards preventing antimicrobial resistance, Smart Blood Analytics Swiss proudly announces the attainment of EU-MDR (European Medical Device Regulation)1 certification for their VIRUS vs. BACTERIA Clinical Decision Support...

at 02:43
January-March 2024 Net sales, which for the quarter only included royalties, amounted to SEK 156 (520)Net earnings amounted to KSEK -2,946 (-51,658), where exchange rate effects of KSEK 21 358 (435) had a substantial impact.Earnings per share before...

at 02:27
Market Overview The Global Biometric Technologies Market is expected to grow at a compound annual growth rate (CAGR) of around 12% between 2024 and 2031, from an estimated USD 38 billion in 2023 to approximately USD 120 billion by 2031. Our study...

at 02:05
Locate Bio, a pioneering orthobiologics company, today announces the successful completion of an oversubscribed £9.2 million funding round from both new investors and existing investors, Mercia Ventures and BGF. The proceeds will fund a clinical...

at 02:05
Positive topline results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of...



News published on and distributed by: